Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 23vPPV and TIV Co-administration
NCT02062281Phase 4Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Nov 2013
- Primary completion
- Dec 2013
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Immunogenicity of 23vPPV at 1 month and Immunogenicity of TIV at 1 month. Started Nov 2013; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02062281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062281.